Brain : a journal of neurology Journal

Overview
Identity
View All

publication venue for

Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?. 147:2601-2603. 2024
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.. 147:2144-2157. 2024
Macroscopic changes in aquaporin-4 underlie blast traumatic brain injury-related impairment in glymphatic function.. 147:2214-2229. 2024
Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.. 147:1680-1695. 2024
Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females.. 147:1497-1510. 2024
Brain morphometry in former American football players: Findings from the DIAGNOSE CTE research project. 2024
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.. 146:4414-4424. 2023
Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.. 146:4508-4519. 2023
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.. 146:3719-3734. 2023
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer's disease.. 146:2928-2943. 2023
Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.. 146:2944-2956. 2023
Tau positron emission tomography in preclinical Alzheimer's disease.. 146:700-711. 2023
Temporopolar regions of the human brain.. 146:20-41. 2023
Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.. 145:4459-4473. 2022
Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.. 145:4506-4518. 2022
Sex-specific effects of microglial activation on Alzheimer's disease proteinopathy in older adults.. 145:3536-3545. 2022
Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline.. 145:2823-2833. 2022
A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer's disease brain.. 145:2528-2540. 2022
Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.. 145:2541-2554. 2022
Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease.. 145:2149-2160. 2022
Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.. 145:2133-2148. 2022
Cortical and subcortical pathological burden and neuronal loss in an autopsy series of FTLD-TDP-type C.. 145:1069-1078. 2022
Proposed research criteria for prodromal behavioural variant frontotemporal dementia.. 145:1079-1097. 2022
Impact of autism genetic risk on brain connectivity: a mechanism for the female protective effect.. 145:378-387. 2022
COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital.. 144:2696-2708. 2021
Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation.. 144:2837-2851. 2021
Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease.. 144:2852-2862. 2021
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.. 144:2186-2198. 2021
The development and convergence of co-pathologies in Alzheimer's disease.. 144:953-962. 2021
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.. 144:515-527. 2021
18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.. 144:266-277. 2021
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.. 143:3816-3826. 2020
Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.. 143:2868-2871. 2020
Genetic variants and functional pathways associated with resilience to Alzheimer's disease.. 143:2561-2575. 2020
Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.. 143:932-943. 2020
Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy.. 143:611-621. 2020
Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.. 143:320-335. 2020
Postoperative delirium is associated with increased plasma neurofilament light.. 143:47-54. 2020
Sex differences in the genetic predictors of Alzheimer's pathology.. 142:2581-2589. 2019
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.. 142:2380-2401. 2019
Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies.. 142:2068-2081. 2019
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects.. 142:1148-1160. 2019
Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.. 142:1077-1092. 2019
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.. 142:1063-1076. 2019
Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.. 142:460-470. 2019
Reply: TDP-43 mutations increase HNRNP A1-7B through gain of splicing function.. 141:-. 2018
Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.. 141:1828-1839. 2018
Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.. 141:1486-1500. 2018
TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis.. 141:1320-1333. 2018
FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.. 141:1201-1217. 2018
Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer's disease.. 140:3301-3316. 2017
Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.. 140:2104-2111. 2017
Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder.. 140:-. 2017
A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction.. 140:1128-1146. 2017
Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism.. 140:98-117. 2016
Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia.. 139:3202-3216. 2016
BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.. 139:2766-2777. 2016
Neural substrates of vulnerability to post-surgical delirium with prospective diagnosis.. 139:-. 2016
Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.. 139:2261-74. 2016
The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.. 139:2249-60. 2016
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.. 139:2063-81. 2016
Neural substrates of vulnerability to postsurgical delirium as revealed by presurgical diffusion MRI.. 139:1282-94. 2016
Reply: Neural substrates of vulnerability to post-surgical delirium with prospective diagnosis.. 139:-. 2016
Free-water imaging in Parkinson's disease and atypical parkinsonism.. 139:495-508. 2015
TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.. 138:3610-22. 2015
Seizures at the scale of individual neurons.. 138:2807-8. 2015
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.. 138:2701-15. 2015
The Wernicke conundrum and the anatomy of language comprehension in primary progressive aphasia.. 138:2423-37. 2015
Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.. 138:1023-35. 2015
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.. 138:963-73. 2015
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.. 138:2659-71. 2015
Identification of the SCA21 disease gene: remaining challenges and promising opportunities.. 137:2626-8. 2014
Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.. 137:1167-75. 2014
Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.. 137:1176-92. 2014
A novel frontal pathway underlies verbal fluency in primary progressive aphasia.. 136:2619-28. 2013
In vivo characterization of the early states of the amyloid-beta network.. 136:2239-52. 2013
A cortical pathway to olfactory naming: evidence from primary progressive aphasia.. 136:1245-59. 2013
Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy.. 136:926-43. 2013
Words and objects at the tip of the left temporal lobe in primary progressive aphasia.. 136:601-18. 2013
Quantitative classification of primary progressive aphasia at early and mild impairment stages.. 135:1537-53. 2012
Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia.. 135:1554-65. 2012
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.. 135:2155-68. 2012
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden.. 134:1635-46. 2011
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.. 134:1077-88. 2011
Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury.. 135:1268-80. 2011
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.. 133:1352-67. 2010
Relationship of dementia screening tests with biomarkers of Alzheimer's disease.. 133:3290-300. 2010
Biomarkers for Alzheimer's disease: ready for the next step.. 132:2002-4. 2009
Neurology of anomia in the semantic variant of primary progressive aphasia.. 132:2553-65. 2009
'The quicksand of forgetfulness': semantic dementia in One hundred years of solitude.. 132:2609-16. 2009
Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.. 131:109-19. 2007
Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations.. 130:1767-76. 2007
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.. 129:3103-14. 2006
3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.. 129:2867-73. 2006
Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury.. 127:2629-35. 2004
Brain responses to nouns, verbs and class-ambiguous words in context.. 2552-66. 2000
Mirth, laughter and gelastic seizures.. 757-80. 1993
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease 2013